FEATURED ARTICLES
The Industry Talks Access — Fabian Sandoval Builds It
Fabian Sandoval is redefining what a clinical research site looks like — building trust through community partnerships, media, and education to improve trial access and awareness long before enrollment begins.
-
Assigned Slot Allocation Offers A Fair Solution For Oncology Phase 1 Trials (Part 2)
In part two of this series on slot allocation, Nehal Lakhani, MD, Ph.D. proposes assigned slot allocation as an alternative to competitive placement and discusses how the approach might benefit patients and sites.
-
Slot Allocation Is A Problem For Patients And PIs In Phase 1 Oncology Trials (Part 1)
Given the shift in the size and scope of oncology Phase 1 trials, cohort management and slot allocation strategies must change, too. Nehal Lakhani, MD, Ph.D. explains why competitive slot allocation is no longer optimal for patients or PIs.
-
Considerations For Allergic Rhinitis Trials Are Nothing To Sneeze At
Inimmune CEO David Burkhart explains how a GSK layoff led to the formation of a new company focused on treating allergic rhinitis. Here, he shares success from the company's approach to site selection, trial design, and timing.